



# MEDICATION ORDERS

## INCLISIRAN (LEQVIO)

Page 1 of 2

| PATIENT INFORMATION                      |                                                                                   |
|------------------------------------------|-----------------------------------------------------------------------------------|
| Patient Name:                            | DOB:                                                                              |
| <input type="checkbox"/> NKDA Allergies: |                                                                                   |
| <input type="checkbox"/> New to Therapy  | <input type="checkbox"/> Continuing Therapy - Last Treatment Date: Next Due Date: |

| REFERRAL STATUS                       |                                                   |                                        |
|---------------------------------------|---------------------------------------------------|----------------------------------------|
| <input type="checkbox"/> New Referral | <input type="checkbox"/> Dose or Frequency Change | <input type="checkbox"/> Order Renewal |

| DIAGNOSIS AND ICD 10 CODE                                                        |                     |
|----------------------------------------------------------------------------------|---------------------|
| <input type="checkbox"/> Heterozygous Familial Hypercholesterolemia              | ICD-10 Code: E78.01 |
| <input type="checkbox"/> Mixed Hyperlipidemia                                    | ICD-10 Code: E78.2  |
| <input type="checkbox"/> Hyperlipidemia, unspecified                             | ICD-10 Code: E78.5  |
| <input type="checkbox"/> Clinical atherosclerotic cardiovascular disease (ASCVD) | ICD-10 Code: I25.10 |
| <input type="checkbox"/> Other:                                                  | ICD-10 Code:        |

| REQUIRED DOCUMENTATION/TESTING                                                  |                                                                                                       |
|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> This signed order form by the provider                 | <input type="checkbox"/> Clinical/Progress notes supporting primary dx                                |
| <input type="checkbox"/> Patient demographics AND insurance info                | <input type="checkbox"/> Verification/documentation that LDL-C has not reached the target of <70mg/dl |
| List Tried & Failed Therapies, including duration of treatment:<br>1)<br><br>2) |                                                                                                       |

| MEDICATION ORDERS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Initial Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | <input type="checkbox"/> Leqvio 284mg subcutaneously on day 1, then Leqvio 284mg subcutaneous in 3 months followed by maintenance in 6 months |
| Maintenance Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | <input type="checkbox"/> Leqvio 284mg subcutaneous every 6 months                                                                             |
| Other Dosing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | <input type="checkbox"/> Leqvio 284mg subcutaneous: _____                                                                                     |
| Refills: <input type="checkbox"/> None <input type="checkbox"/> x 6 months <input type="checkbox"/> x 1 year <input type="checkbox"/> Other:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                               |
| Treatment Labs:<br><input checked="" type="checkbox"/> Pregnancy test within 72 hours prior to initiation of therapy for female patient under 55 years of age and no history of surgical hysterectomy.<br><input type="checkbox"/> No additional pre-treatment lab test required at the infusion site. Routine lab monitoring required by the FDA will be assessed and managed by the referring provider.<br><input type="checkbox"/> Other Labs and Frequency: _____                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                               |
| <ul style="list-style-type: none"><li>• New orders and progress notes required at least once yearly. A medication substitution may be required based on insurance payer policy due to preferred versus non-preferred medications or based on payer step therapy guidelines.</li><li>• Please note for patients receiving treatment at the Montgomery Cancer Center: if an infusion reaction occurs, the Montgomery Cancer Center provider will order appropriate rescue medications as deemed medically necessary. This may also include pausing, reducing the rate of infusion or discontinuing the medication.</li><li>• Please note for patient receiving treatment at Baptist East Outpatient Infusion: if an infusion reaction occurs, the Baptist East staff will follow the PRN hypersensitivity standing orders and will contact the referring provider in the event of an emergency. For life threatening anaphylaxis, Baptist East staff will follow rapid response policy or 911 facility policy.</li></ul> |                                                                                                                                               |
| Physician Signature: _____ Date: _____                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                               |

Patient Name: \_\_\_\_\_ Patient Date of Birth: \_\_\_\_\_



## MEDICATION ORDERS

### INCLISIRAN (LEQVIO)

Page 2 of 2

All order sets will include a statement to activate these PRN hypersensitivity standing orders when necessary.

| REACTION SYMPTOMS                                                         |   | DRUG                                | DOSE     | ROUTE |
|---------------------------------------------------------------------------|---|-------------------------------------|----------|-------|
| Fever, chills and or rigors                                               | ✓ | Acetaminophen<br>(Tylenol)          | 1000mg   | PO    |
| Itching, facial flushing, hives, rash                                     | ✓ | Diphenhydramine<br>(Benadryl)       | 50mg     | IVP   |
|                                                                           | ✓ | Famotidine<br>(Pepcid)              | 20mg     | IVP   |
|                                                                           | ✓ | Methylprednisolone<br>(Solu-Medrol) | 125mg    | IVP   |
| Hypotension, wheezing, shortness of breath,<br>facial/lip/tongue swelling | ✓ | Normal Saline                       | 150ml/hr | IV    |
|                                                                           | ✓ | Diphenhydramine<br>(Benadryl)       | 50mg     | IVP   |
|                                                                           | ✓ | Methylprednisolone<br>(Solu-Medrol) | 125mg    | IVP   |
|                                                                           | ✓ | Hydrocortisone<br>(Solu-Cortef)     | 50mg     | IVP   |
|                                                                           | ✓ | Epinephrine Pen                     | 0.3mg    | IM    |
| Nausea/Vomiting                                                           | ✓ | Granisetron<br>(Kytril)             | 1mg      | IVP   |

| PROVIDER INFORMATION        |       |                    |      |
|-----------------------------|-------|--------------------|------|
| Office Contact Name:        |       |                    |      |
| Prescribing Providers Name: |       | Provider NPI:      |      |
| Office Address:             | City: | State:             | Zip: |
| Office Phone Number:        |       | Office Fax Number: |      |
| Physician Signature:        |       | Date:              |      |

For questions, please contact  
Baptist Outpatient Infusion Services @ (334) 747-7401

Fax completed form and all documentation to  
Baptist Outpatient Infusion Services @ (334) 747-7403